美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Novo Nordisk A/S B Shares ADRhedged

25.44

-0.6090-2.34%

盤後：25.440.00000.00%16:10 EST

成交量：5,315.00

成交額：13.55萬

市值：407.04萬

市盈率：- -

高：25.91

開：25.05

低：25.05

收：26.05

52周最高：54.13

52周最低：23.29

股本：16.00萬

流通股本：6.00萬

量比：1.07

換手率：8.86%

股息：0.65

股息率：2.57%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

2026，全球暢銷藥Top10(預測版)

超級大洗牌！跨國藥企中國市場最新排名

速遞｜擴建海外供應鏈，諾和諾德要把愛爾蘭打造成口服司美格魯肽供應中心

GLP1减重宝典

諾和諾德明星減肥口服藥上市第五周，處方量超3.8萬份

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":25.44,"timestamp":1771621200000,"preClose":26.049,"halted":0,"volume":5315,"hourTrading":{"tag":"盘后","latestPrice":25.44,"preClose":25.44,"latestTime":"16:10 EST","volume":6,"amount":152.64,"timestamp":1771621804254,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02337901646896227,"floatShares":60000,"shares":160000,"eps":0,"marketStatus":"休市中","change":-0.609,"latestTime":"02-20 16:00:00 EST","open":25.05,"high":25.9144,"low":25.05,"amount":135486.4327,"amplitude":0.033184,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":26.049,"dividendRate":0.025684,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.44,"preClose":25.44,"latestTime":"16:10 EST","volume":6,"amount":152.64,"timestamp":1771621804254,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0734338131606713},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":60000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0734338131606713,"shares":160000,"dividePrice":0.6534,"high":25.9144,"amplitude":0.033184,"preClose":26.049,"low":25.05,"week52Low":23.2926,"pbRate":"--","week52High":54.13,"institutionHeld":0,"latestPrice":25.44,"eps":0,"divideRate":0.025684,"volume":5315,"delay":0,"ttmEps":0,"open":25.05,"prevYearClose":27.4362,"prevWeekClose":26.325,"prevMonthClose":31.55,"prevQuarterClose":27.4362,"fiveDayClose":26.12,"twentyDayClose":33.4001,"sixtyDayClose":26.4998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612236099","title":"2026，全球暢銷藥Top10(預測版)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612236099","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612236099?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 17:02","pubTimestamp":1771491774,"startTime":"0","endTime":"0","summary":"在简讯中，Evaluate Pharma分析师对2026年全球十大畅销药品的销售额、排名变动做出专业预测，揭开了未来医药市场的竞争走向。与上一年的预测相比，2026年全球TOP10畅销药品的产品阵容保持不变，但整体销售额有明显的攀升，预计TOP10产品总销售额将接近两千亿美元关口，同比增长达到18%。Eliquis在2026年预计销售额将达121亿美元，但这个极大可能是Eliquis最后一次入选TOP10畅销药榜单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219172854954174a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2361045086.USD","LU0477156953.USD","LU1069347547.HKD","LU1699723380.USD","LU0203345920.USD","LU1941712348.USD","BK4516","IE00BZ1G4Q59.USD","LU0203347892.USD","LU2106854487.HKD","IE00B4R5TH58.HKD","NVOX","LU2125154935.USD","LU1201861249.SGD","SG9999001176.SGD","LU0106261372.USD","SG9999002232.USD","SG9999015358.SGD","LU0965509010.AUD","SG9999014559.SGD","SG9999014575.USD","IE00BN8TJ469.HKD","LU0098860793.USD","LU1066051225.USD","LU0985320562.USD","LU2023250843.SGD","SG9999001176.USD","LU1917777945.USD","LU0861579265.USD","LU1023059063.AUD","LU1057294990.SGD","LU0320765646.SGD","SG9999015341.SGD","LU1061106388.HKD","LU2112291526.USD","LU0234572021.USD","LU1037948897.HKD","LU0154236417.USD","LU0265550359.USD","LU0070302665.USD","LU0130517989.USD","LU1037948541.HKD","LU0320765489.SGD","LU0432979614.USD","LU2360032135.SGD","BK4588","LU2023250504.SGD","LU0058720904.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0266013472.USD","SG9999014542.SGD","LU1035773651.USD","BK4559","IE00B2B36J28.USD","LU1066051498.USD","SGXZ57979304.SGD","LU1571399168.USD","LU0238689110.USD","BK4532","SG9999001440.SGD","LU1066051811.HKD","LU1116320737.USD","LU1983299246.USD","LU1066053197.SGD","LU0965509283.SGD","LU0289739699.SGD","LU1093756168.USD","LU2125154778.USD","BK4534","LU0965509101.SGD","LU2461242641.AUD","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU1934455277.USD","SG9999002224.SGD","LU1941712264.USD","LU0980610538.SGD","BK4007","LU0265550946.USD","LU2361044865.SGD","LU1291159041.SGD","LU1430594728.SGD","LU2361044949.HKD","LU0211331839.USD","LU0130102774.USD","IE00BKVL7J92.USD","LU0122379950.USD","LU1585245621.USD","LU1974910355.USD","SG9999014567.USD","LU2468319806.SGD","LU2089984988.USD","BK4550","LU1989772923.USD","LU0965508806.USD","LU1929549753.HKD","IE0009355771.USD","LU1989772840.SGD","IE00BSNM7G36.USD","BK4599","LU1162221912.USD","LLY","LU1116320901.HKD","IE00BLSP4452.SGD","LU0006306889.USD","NVO","LU2324357040.USD","IE00B1BXHZ80.USD","LU1989771016.USD","SG9999013999.USD","MRK","BK4585","LU0648001328.SGD","LU1093756325.SGD","NVOH","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0208291251.USD","LU1934455194.USD","BK4533","IE00BFTCPJ56.SGD","LU1934455863.HKD"],"gpt_icon":1},{"id":"2611486068","title":"超級大洗牌！跨國藥企中國市場最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611486068?lang=zh_tw&edition=fundamental","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CWEB","KWEB","LU1093756325.SGD","BK4599","NVOH","IE00BKVL7J92.USD","MRK","BK4532","DRAG","BK4585","LU0154236417.USD","LU1093756168.USD","BK4504","RHHBY","LU0963586101.USD","NVS","BK4588","AZN","BK4007","CQQQ","IE00BZ1G4Q59.USD","ASHR","BK4614","NVOX","MCHI","NVO","ASHS","LLY"],"gpt_icon":1},{"id":"2611412110","title":"速遞｜擴建海外供應鏈，諾和諾德要把愛爾蘭打造成口服司美格魯肽供應中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2611412110","media":"GLP1减重宝典","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611412110?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 22:57","pubTimestamp":1771081043,"startTime":"0","endTime":"0","summary":"至于这次针对口服Wegovy的扩建规模，诺和诺德对外没有给出具体投资额、扩建面积或新增产能的明确数字，但把它定义为非美市场的全球供应中心，本身已经说明其产线与放量节奏会被提升到公司级优先级。诺和诺德之所以要把“非美市场”明确交给爱尔兰，还与它在美国本土的扩产路径同步推进有关。与此同时，诺和诺德在爱尔兰的产能选择也体现出“速度优先”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423132697a63940&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423132697a63940&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","NVO","BK4599","NVOX","BK4588","BK4007","BK4585","NVOH"],"gpt_icon":1},{"id":"2611152972","title":"諾和諾德明星減肥口服藥上市第五周，處方量超3.8萬份","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152972","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152972?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 20:50","pubTimestamp":1770987013,"startTime":"0","endTime":"0","summary":"据路透社2月13日消息，IQVIA数据显示，丹麦制药公司诺和诺德（NVO.US）的明星减肥药Wegovy在上市第五周的处方量达到了38,220份。Wegovy是诺和诺德公司开发的一种用于治疗肥胖症的药物。自上市以来，该药物在美国市场的处方量持续增长，显示出其市场需求强劲。随着越来越多的医生和患者了解和认可Wegovy的疗效，预计其处方量还将进一步上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213205119a4a0e331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4532","BK4007","NVO","NVOH","LU1093756325.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","BK4585","NVOX","BK4588"],"gpt_icon":0}],"pageSize":4,"totalPage":20,"pageCount":1,"totalSize":79,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOH\",params:#limit:6,delay:false,,,undefined,":[]}}